Engineered T Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Chimeric Antigen Receptor, T Cell Receptor, Tumor-Infiltrating Lymphocytes), By Application (Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Melanoma), By End-User (Cancer Research Centers, Clinics, Hospitals, Others), By Region and Competition, 2020-2030F

Market Overview

Global Engineered T Cells Market was valued at USD 26.31 Billion in 2024 and is expected to reach USD 136.26 Billion in the forecast period with a CAGR of 31.51% through 2030. The Global Engineered T Cells Market is witnessing significant growth, driven by rapid advancements in cellular immunotherapy and increasing adoption of engineered T cell therapies for cancer treatment. Engineered T cells, particularly chimeric antigen receptor T cells (CAR-T) and T cell receptor (TCR-T) therapies, have revolutionized the approach to cancer care by harnessing the body's immune system to target and eliminate malignant cells. Growing research in synthetic biology and gene editing has enhanced the safety, efficacy, and durability of these therapies, making them a promising solution for various hematologic malignancies and solid tumors. With regulatory bodies expediting approvals and expanding indications for engineered T cell therapies, biotechnology firms and pharmaceutical companies are investing heavily in research and development to optimize therapy designs, improve manufacturing processes, and expand clinical applications. The market is further supported by increasing patient awareness, rising healthcare expenditure, and growing collaborations between academic institutions and industry players to accelerate innovation.

The market is driven by multiple factors, including breakthroughs in gene modification technologies such as CRISPR-Cas9, which enhance T cell engineering precision and efficacy. The shift toward personalized medicine is boosting demand for customized engineered T cell therapies tailored to individual patient profiles. Advancements in automation and bioprocessing are streamlining large-scale manufacturing, reducing production costs, and making these therapies more accessible. The emergence of off-the-shelf allogeneic engineered T cells is addressing scalability and donor-related limitations, allowing for broader patient reach. The expanding application of engineered T cells beyond oncology, particularly in treating autoimmune disorders and infectious diseases, is creating new growth avenues. The integration of artificial intelligence (AI) in T cell therapy research is further improving target identification, optimizing therapy design, and accelerating drug discovery, fueling market expansion.

Despite the strong growth trajectory, challenges remain in the widespread adoption of engineered T cell therapies. High treatment costs and complex manufacturing processes limit affordability and accessibility, posing a significant barrier for patients and healthcare providers. Safety concerns related to cytokine release syndrome (CRS) and neurotoxicity present risks that require continuous monitoring and mitigation strategies. The lack of standardized regulatory frameworks across different countries delays therapy approvals and market entry. Limited availability of specialized infrastructure and skilled professionals to administer and monitor engineered T cell therapies further hampers growth. Addressing these challenges requires ongoing advancements in manufacturing efficiency, regulatory harmonization, and investments in healthcare infrastructure to ensure the safe and effective integration of engineered T cells into mainstream clinical practice.

Key Market Drivers

Advancements in Immunotherapy Research

​Immunotherapy research has become a beacon of hope in healthcare, particularly in cancer treatment. Engineered T cell therapies, such as Chimeric Antigen Receptor T-cell (CAR-T) and T-cell Receptor T-cell (TCR-T) therapies, have gained significant attention due to their potential to harness the immune system's power for targeted disease treatment.​

These therapies are a product of an enhanced understanding of the human immune system. Scientists have unraveled the complexities of immune responses, enabling the development of innovative treatments. For instance, CAR-T cell therapy involves modifying a patient's T cells to recognize and attack cancer cells. Since the approval of the first CAR-T cell therapy in 2017, more than 30,000 patients with blood cancers have been treated, with some experiencing long-lasting remissions of a decade or more. ​

The era of precision medicine has been ushered in by immunotherapy research. Tailoring treatments to individual patients based on their unique genetic makeup and the molecular characteristics of their diseases has become a reality. Engineered T cell therapies exemplify this approach, as they can be customized to recognize specific antigens present on cancer cells, sparing healthy cells and minimizing side effects. As of April 2023, six CAR-T cell therapies have been approved by the FDA for various hematologic malignancies, including B-cell acute lymphoblastic leukemia and multiple myeloma. ​

Originally designed for cancer treatment, engineered T cell therapies are now finding applications in other disease areas. Researchers are exploring their potential in autoimmune disorders and infectious diseases. Advancements in understanding the immune system's role in various diseases are driving this expansion, broadening the scope of the engineered T cells market.​

Safety profiles of engineered T cell therapies have improved significantly due to ongoing research. Early iterations of CAR-T therapies were associated with severe side effects, but refinements in design and administration protocols have enhanced their safety. For example, the FDA has modified the risk evaluation and mitigation strategies for CAR-T cell therapies to minimize burdens on the healthcare delivery system, indicating confidence in the improved safety profiles of these treatments. ​

Furthermore, immunotherapy research has facilitated the identification and validation of new therapeutic targets. As researchers uncover novel antigens and markers associated with diseases, they can design T cells that precisely target these elements, thereby increasing the therapies' effectiveness. This continuous evolution in immunotherapy research is propelling the growth of the global engineered T cells market, offering promising avenues for disease treatment.

Success in Treating Hematological Cancers

The success stories emerging from the treatment of hematological cancers have been remarkable, particularly with therapies like Chimeric Antigen Receptor T-cell (CAR-T) and T-cell Receptor T-cell (TCR-T) therapies demonstrating exceptional efficacy. This success is not only transforming patient outcomes but also propelling the rapid growth of the global engineered T cells market.​

Engineered T cell therapies have shown unprecedented effectiveness in treating hematological malignancies such as leukemia and lymphoma. Clinical trials have reported remarkable response rates and durable remissions in patients who had exhausted conventional treatment options. For instance, a study involving the CD19-targeting CAR-T therapy axicabtagene ciloleucel (axi-cel) demonstrated an objective response rate (ORR) of 82%, with a complete response (CR) rate of 54% in patients with relapsed/refractory large B-cell lymphoma. At 18 months post-treatment, the overall survival rate was 52%. ​

Certain hematological cancers, particularly relapsed or refractory cases, have historically been challenging to treat. Engineered T cell therapies are altering this narrative by providing viable options for patients with limited alternatives. The U.S. Food and Drug Administration (FDA) has approved several CAR-T therapies for various blood cancers, including acute lymphoblastic leukemia (ALL) and multiple myeloma. As of April 2023, six CAR-T cell therapies have received FDA approval, underscoring their growing significance in oncology. ​

The success of these therapies has led to increased advocacy for broader patient access. Healthcare providers, patient advocacy groups, and policymakers are recognizing the transformative potential of engineered T cell treatments and are working to make them more accessible. This push is further supported by substantial investments in research and development from pharmaceutical companies, biotechnology firms, and academic institutions. These investments are driving innovation, accelerating clinical trials, and expanding the market. For example, the development of novel CAR-T therapies targeting B cell maturation antigen (BCMA) has shown promise in treating multiple myeloma, with studies indicating high response rates and durable remissions. ​

Furthermore, ongoing research is exploring the potential applications of engineered T cell therapies beyond hematological cancers, including solid tumors and autoimmune diseases. This diversification is broadening the market and increasing the potential patient pool. As clinical trials and commercialization efforts expand globally, patients worldwide stand to benefit from these groundbreaking treatments, opening new opportunities and driving growth in the global engineered T cells market.

Expanding Indications

Engineered T cell therapies, including CAR-T (Chimeric Antigen Receptor T-cell) and TCR-T (T-cell Receptor T-cell) therapies, have made remarkable strides in the treatment of various diseases, most notably hematological cancers. However, their potential extends far beyond their initial applications. The ongoing exploration of expanded indications is emerging as a powerful driver for the growth of the global engineered T cells market.

The expansion of indications for engineered T cell therapies represents a significant breakthrough in modern medicine. These therapies have the potential to diversify treatment options for patients across a broad spectrum of diseases, both in oncology and beyond. As new indications emerge, patients previously lacking effective treatments can now find hope in these innovative therapies.

While engineered T cell therapies initially gained prominence in treating blood-related cancers, researchers have been diligently working to apply these treatments to solid tumors. Success in this area would represent a major paradigm shift in oncology, expanding the addressable patient population exponentially. Engineered T cells have demonstrated promise in clinical trials targeting a range of solid tumor types, including lung, breast, and prostate cancer.

Another exciting avenue of exploration for engineered T cell therapies is the treatment of autoimmune diseases. By reprogramming T cells to regulate the immune response, these therapies hold the potential to alleviate the symptoms and halt the progression of conditions such as rheumatoid arthritis, multiple sclerosis, and Crohn's disease. Success in this area could dramatically improve the quality of life for millions of patients.

Engineered T cell therapies are also being investigated as a means of combatting infectious diseases. Researchers are exploring ways to modify T cells to target viruses such as HIV and hepatitis. These therapies have the potential not only to treat infections directly but also to enhance the body's immune response, offering a multifaceted approach to viral diseases.

Rare diseases often present unique challenges in terms of treatment development. Engineered T cell therapies, with their adaptability and precision, offer a promising avenue for addressing rare genetic disorders. The ability to customize these therapies to target specific genetic mutations holds great potential for improving the lives of individuals with rare diseases.

Expanded indications for engineered T cell therapies are particularly promising for pediatric patients. Many children suffer from rare and aggressive forms of cancer, autoimmune diseases, and genetic disorders. Engineered T cell therapies offer a ray of hope for these young patients who may have exhausted conventional treatment options.

The exploration of expanded indications has attracted significant investment from pharmaceutical companies, venture capitalists, and research institutions. The potential to apply these therapies across a broader spectrum of diseases has fueled innovation and accelerated the development of new treatment modalities. This influx of capital is driving market growth and supporting the advancement of engineered T cell technologies.

Increasing Investment

​The global engineered T cells market, encompassing groundbreaking therapies like CAR-T (Chimeric Antigen Receptor T-cell) and TCR-T (T-cell Receptor T-cell), is on a trajectory of rapid expansion, significantly propelled by substantial investments in research, development, and commercialization efforts. This influx of capital is advancing scientific progress and driving market growth.​

Increased funding has led to a surge in clinical trials. As of January 25, 2023, there were 1,087 CAR-T cell clinical trials registered globally, reflecting a robust commitment to advancing these therapies. This acceleration in clinical research facilitates quicker regulatory approvals and expedites the availability of new treatments to patients, thereby stimulating market expansion.​

Substantial investments have also been directed toward enhancing manufacturing infrastructure. Companies like Cellares are developing automated systems, such as the Cell Shuttle, to produce CAR-T cells more efficiently and cost-effectively. These advancements ensure broader patient access to therapies, further bolstering market growth.​

In summary, the engineered T cells market's rapid growth is intricately linked to substantial investments that enhance research capabilities, accelerate clinical trials, improve manufacturing infrastructure, and attract top-tier talent, collectively propelling the market's expansion.

Download Free Sample Report

Key Market Challenges

Manufacturing Complexity

The manufacturing of engineered T cell therapies is intricate and requires stringent quality control. Maintaining the viability and functionality of T cells during the manufacturing process is critical. Scaling up production to meet the demand for these therapies can be challenging, and any variation in manufacturing conditions can impact treatment efficacy.

Safety Concerns

While engineered T cell therapies have shown remarkable efficacy, they are not without safety concerns. Cytokine release syndrome (CRS) and neurologic toxicities are known side effects, and in some cases, these adverse events can be severe. Striking the right balance between maximizing the therapeutic effect and minimizing side effects remains a significant challenge.

Limited Target Antigens

The success of CAR-T therapies relies on the identification of specific target antigens present on cancer cells. Finding suitable antigens for all types of cancer can be challenging, limiting the range of cancers that can be effectively treated with engineered T cells. Expanding the repertoire of target antigens is essential for the market's growth.

Key Market Trends

Expansion into Solid Tumors

While CAR-T therapies initially gained prominence in treating hematological cancers, researchers are increasingly focused on expanding their applications to solid tumors. Emerging clinical trials and research efforts are exploring ways to overcome the unique challenges of treating solid tumors with engineered T cells, offering hope to a broader range of cancer patients.

Combination Therapies

Combination therapies that integrate engineered T cell therapies with other treatment modalities, such as checkpoint inhibitors, targeted therapies, or traditional chemotherapy, are gaining momentum. These synergistic approaches are expected to improve treatment outcomes and reduce the risk of resistance, making them a key trend to watch.

Segmental Insights

Type Insights

Based on the Type, Chimeric Antigen Receptor emerged as the dominant segment in the Global Engineered T Cells Market in 2024. CAR-T cell therapy represents an innovative approach to tumor immunotherapy in cancer treatment. It is widely recognized for its effectiveness in treating acute B lymphocytic leukemia, and numerous clinical trials have been conducted using CAR-T cell therapy for various cancer types. This approach is highly specialized and adaptable because it allows for the modification of the antigen-binding region to target different tumor markers.

Furthermore, CAR-T cells have the capacity to create lasting immune memories in patients with advanced leukemia. CARs, which are recombinant receptors, bind to tumor antigens and activate T cells. These CAR-T cells can directly recognize tumor-specific antigens on the surface of cancer cells and multiply, leading to the destruction of tumor cells. Each patient can receive a personalized CAR T-cell therapy by collecting their T cells and genetically engineering them to express chimeric antigen receptors (CARs) on their cell surfaces. CARs enable the identification and binding to antigens or proteins on the outermost layer of cancer cells.

Application Insights

Based on the Application, Lung Cancer emerged as the dominant segment in the Global Engineered T Cells Market in 2024. Engineered T cells offer a promising avenue for the treatment of lung cancer and various other malignancies, as they can be tailored to target and combat cancer cells within the body. The field of T-cell therapies has evolved significantly through ongoing research and development endeavors, presenting potential benefits for patients with lung cancer and the broader domain of immunotherapy. To illustrate, taking into account the American Cancer Society's estimates for lung cancer in the United States in 2023, it is anticipated that there will be approximately 117,550 new cases of this disease, with the majority (117,340) occurring in males. Additionally, the projections indicate around 120,790 deaths related to lung cancer, with a significant number (59,910) occurring among women.

Download Free Sample Report

Regional Insights

In 2024, North America held the largest share of revenue in the engineered T cells market, and this dominant position is expected to persist throughout the projected period. North America is home to some of the world's leading pharmaceutical and biotechnology firms. These companies have made substantial investments in the research of modified T cells, paving the way for groundbreaking treatments and tools. The healthcare system in North America is well-established and boasts prestigious hospitals, clinics, and medical research facilities. This robust infrastructure facilitates the development and testing of new treatments, including modified T cells, in patients. Venture capital firms, private equity investors, and government programs have injected significant financial support into biotech and medical research in North America. This funding has facilitated the growth of both emerging and established businesses engaged in the development of modified T-cell treatments.

According to data from the National Cancer Institute, breast cancer is the most prevalent cancer type, with an anticipated 300,590 new cases in the United States in 2023. Cellular therapies, including modified T cells, have been developed and approved with the assistance of the US Food and Drug Administration (FDA). The accelerated review processes and simplified regulatory pathways in the region have encouraged companies to focus their research efforts in North America.

Meanwhile, the Asia Pacific region is poised to experience the fastest growth in the engineered T cells market during the forecasted period. The increasing incidence of cancer and other chronic diseases in Asia has elevated the demand for innovative and personalized therapies like modified T-cell treatments. The vast and diverse population of the Asia Pacific region provides a substantial pool of patients for clinical trials and the adoption of these treatments. Moreover, developed nations such as China, Japan, South Korea, and India have been actively developing and marketing engineered T-cell therapies due to enhancements in healthcare infrastructure and biotechnology research capabilities.

Recent Developments

• In August 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel (afami-cel, Tecelra) for metastatic synovial sarcoma, marking the first engineered cell therapy approved for a solid tumor. This milestone introduces the first new treatment for synovial sarcoma in over a decade, a rare soft tissue cancer primarily affecting young adults. Developed by Adaptimmune, afami-cel is approved for adults with unresectable or metastatic synovial sarcoma who have undergone chemotherapy and meet specific human leukocyte antigen (HLA) and tumor expression criteria.
• In June 2023, CERo Therapeutics, an immunotherapy company developing next-generation engineered T cell therapies, announced a definitive merger agreement with Phoenix Biotech Acquisition Corp., a special purpose acquisition company. Upon completion of the transaction, expected in the second half of 2023, the merged entity will operate as CERo Therapeutics Holdings, Inc., led by CERo and PBAX’s leadership.
• In May 2023, Eterna Therapeutics completed the acquisition of the global immuno-oncology platform from Exacis Biotherapeutics. According to Eterna representatives, this acquisition strengthens the company's core operations by adding a portfolio of allogeneic immuno-oncology drugs currently under development, targeting both solid and hematologic cancers. Additionally, as part of the agreement, Eterna secures an exclusive global license to produce an unlimited range of mRNA-engineered T-cell and natural killer (NK) therapies derived from induced pluripotent stem cells (iPSCs).
• In May 2023, Anixa Biosciences, Inc., a biotechnology firm specializing in cancer diagnosis, treatment, and prevention, announced that it had initiated the treatment of another patient in an ongoing clinical study of its innovative chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer. This endeavor is carried out in collaboration with Moffitt Cancer Center, the institution with which Anixa partners.
• In March 2023, the publicly disclosed definitive agreement between Adaptimmune Therapeutics plc and TCR2 Therapeutics Inc. outlined their merger in an all-stock transaction. This merger is aimed at establishing a world-class cell therapy enterprise with a focus on solid tumors. The merger is expected to offer significant benefits in terms of product delivery and clinical development, facilitated by complementary technological frameworks. Consequently, the combined company's financial runway is anticipated to extend through 2026 following the completion of the merger. 

Key Market Players

• Amgen Inc
• Athenex, Inc.
• Bellicum Pharmaceuticals Inc
• Bristol-Myers Squibb Co
• Eli Lilly & Co
• Gilead Sciences Inc
• Novartis AG
• Oxford Biomedica PLC
• Pfizer Inc
• Precision BioSciences Inc

 Report Scope:

In this report, the Global Engineered T Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Engineered T Cells Market, By Type:

o   Chimeric Antigen Receptor

o   T Cell Receptor

o   Tumor-Infiltrating Lymphocytes

• Engineered T Cells Market, By Application:

o   Breast Cancer

o   Colorectal Cancer

o   Leukemia

o   Lung Cancer

o   Melanoma

• Engineered T Cells Market, By End-User:

o   Cancer Research Centers

o   Clinics

o   Hospitals

o   Others

• Engineered T Cells Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  Germany

§  United Kingdom

§  France

§  Italy

§  Spain

o   Asia-Pacific

§  China

§  Japan

§  India

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Engineered T Cells Market.

Available Customizations:

Global Engineered T Cells market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Engineered T Cells Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com